161 related articles for article (PubMed ID: 15370724)
1. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
Färber L; Stratz TH; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Welzel D; Müller W;
Int J Clin Pharmacol Res; 2001; 21(1):1-13. PubMed ID: 11708570
[TBL] [Abstract][Full Text] [Related]
3. Fibromyalgia treatment with intravenous tropisetron administration.
Stratz T; Färber L; Varga B; Baumgartner C; Haus U; Müller W
Drugs Exp Clin Res; 2001; 27(3):113-8. PubMed ID: 11447769
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
5. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group.
Färber L; Stratz T; Brückle W; Späth M; Pongratz D; Lautenschläger J; Kötter I; Zöller B; Peter HH; Neeck G; Alten R; Müller W
Scand J Rheumatol Suppl; 2000; 113():49-54. PubMed ID: 11028832
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
Holman AJ; Myers RR
Arthritis Rheum; 2005 Aug; 52(8):2495-505. PubMed ID: 16052595
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
Vergne-Salle P; Dufauret-Lombard C; Bonnet C; Simon A; Trèves R; Bonnabau H; Bertin P
Eur J Pain; 2011 May; 15(5):509-14. PubMed ID: 21036635
[TBL] [Abstract][Full Text] [Related]
9. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain.
Haus U; Varga B; Stratz T; Späth M; Müller W
Scand J Rheumatol Suppl; 2000; 113():55-8. PubMed ID: 11028833
[TBL] [Abstract][Full Text] [Related]
10. Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
Stratz T; Kees F; Müller W
Drugs Exp Clin Res; 2003; 29(2):91-4. PubMed ID: 12951840
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled trial of a single dose of tropisetron for the prevention of vomiting after strabismus surgery in children.
Tosun Z; Akin A; Dogan H; Boyaci A
Mt Sinai J Med; 2006 Dec; 73(8):1106-11. PubMed ID: 17285204
[TBL] [Abstract][Full Text] [Related]
12. Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial.
Lambert RG; Hutchings EJ; Grace MG; Jhangri GS; Conner-Spady B; Maksymowych WP
Arthritis Rheum; 2007 Jul; 56(7):2278-87. PubMed ID: 17599747
[TBL] [Abstract][Full Text] [Related]
13. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial.
Russell IJ; Perkins AT; Michalek JE;
Arthritis Rheum; 2009 Jan; 60(1):299-309. PubMed ID: 19116896
[TBL] [Abstract][Full Text] [Related]
14. Results of the intravenous administration of tropisetron in fibromyalgia patients.
Müller W; Stratz T
Scand J Rheumatol Suppl; 2000; 113():59-62. PubMed ID: 11028834
[TBL] [Abstract][Full Text] [Related]
15. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study.
Hrycaj P; Stratz T; Mennet P; Müller W
J Rheumatol; 1996 Aug; 23(8):1418-23. PubMed ID: 8856622
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
17. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
[TBL] [Abstract][Full Text] [Related]
18. Treatment of tendopathies with tropisetron.
Stratz T; Varga B; Müller W
Rheumatol Int; 2002 Nov; 22(6):219-21. PubMed ID: 12426658
[TBL] [Abstract][Full Text] [Related]
19. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
20. [Pain modification by the 5-HT3 receptor antagonist tropisetron in secondary fibromyalgias].
Stratz T; Müller W
Fortschr Med Orig; 2002; 120(1):17-20. PubMed ID: 14518353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
